Global Nervous System Markers Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Nervous System Markers Market Research Report 2024
A major percentage of world population is affected by neurological disorders, this in turn is causing major disabilities globally. Due to the high incidence of neurological disorders, there is the need for biomarkers as biomarkers measure biological states and are used for indication of both pathogenic as well as normal biological process in terms of therapeutic intervention. Biomarkers can also be utilized in combination for accessing the state of the disease of an individual.
According to Mr Accuracy reports new survey, global Nervous System Markers market is projected to reach US$ 808.7 million in 2029, increasing from US$ 543.6 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029.
According to the "Global Use of Medicines 2024" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China's drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few yearsFrom the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nervous System Markers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Athena Diagnostics
Myriad RBM
QIAGEN
Thermo Fisher Scientific
Segment by Type
Imaging Biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Depression
Schizophrenia
Huntington's Disease
Parkinson's Disease
Alzheimer's Disease
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Nervous System Markers report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Nervous System Markers market is projected to reach US$ 808.7 million in 2029, increasing from US$ 543.6 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029.
According to the "Global Use of Medicines 2024" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China's drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few yearsFrom the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nervous System Markers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Athena Diagnostics
Myriad RBM
QIAGEN
Thermo Fisher Scientific
Segment by Type
Imaging Biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
Segment by Application
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Depression
Schizophrenia
Huntington's Disease
Parkinson's Disease
Alzheimer's Disease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Nervous System Markers report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices